Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Sharma P, et al. Among authors: ohyama c. Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26. Lancet Oncol. 2017. PMID: 28131785 Clinical Trial.
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Hoshi S, Ohyama C, Ono K, Takeda A, Yamashita S, Yamato T, Itoh A, Satoh M, Saito S, Okada Y, Sohma F, Arai Y. Hoshi S, et al. Among authors: ohyama c. Int J Clin Oncol. 2004 Apr;9(2):125-9. doi: 10.1007/s10147-003-0379-8. Int J Clin Oncol. 2004. PMID: 15108045
Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Koie T, Ohyama C, Hashimoto Y, Hatakeyama S, Yamamoto H, Yoneyama T, Kamimura N. Koie T, et al. Among authors: ohyama c. Int J Clin Oncol. 2013 Aug;18(4):724-30. doi: 10.1007/s10147-012-0447-z. Epub 2012 Jul 19. Int J Clin Oncol. 2013. PMID: 23011100 Clinical Trial.
Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association.
Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T; Cancer Registration Committee of the Japanese Urological Association; Ohyama C, Nishiyama H, Fujisawa M, Uemura H, Fujimoto H, Suzuki K, Eto M, Hara I, Matsubara A, Nonomura N, Nakanishi H, Koie T, Kanayama H, Miki T, Fukumori T, Naito S; Cancer Registration Committee of the Japanese Urological Association. Koie T, et al. Among authors: ohyama c. Jpn J Clin Oncol. 2016 May;46(5):468-74. doi: 10.1093/jjco/hyw005. Epub 2016 Feb 6. Jpn J Clin Oncol. 2016. PMID: 26851754
Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
Hosogoe S, Hatakeyama S, Kusaka A, Hamano I, Iwamura H, Fujita N, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ohyama C. Hosogoe S, et al. Among authors: ohyama c. Eur Urol Focus. 2018 Dec;4(6):946-953. doi: 10.1016/j.euf.2017.03.013. Epub 2017 Apr 7. Eur Urol Focus. 2018. PMID: 28753881 Free article.
556 results